<DOC>
	<DOCNO>NCT00901186</DOCNO>
	<brief_summary>This study ass efficacy safety ranibizumab ( intravitreal injection ) versus laser treatment patient visual impairment due diabetic macular edema .</brief_summary>
	<brief_title>Efficacy Safety Ranibizumab ( Intravitreal Injections ) Versus Laser Treatment Patients With Visual Impairment Due Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Diabetes mellitus 1 2 , HbA1c &lt; 11.0 % , With : Clinically significant Diabetic Macular Edema least one eye . 2 . Previous treatment macular photocoagulation consider investigator believe study eye may possibly benefit additional photocoagulation . 3 . Best correct visual acuity score 78 25 letter ( Early Treatment Diabetic Retinopathy Study ETDRS Chart 4 meter ) . 4 . Central foveal thickness &gt; 250Âµm ( Optical Coherence Tomography ) . 5 . Diabetes medication stable 3 month prior . In study eye : 1 . Active intraocular inflammation . 2 . Any active infection . 3 . History uveitis . 4 . Structural damage within 500 micron center macula . 5 . Neovascularization iris . 6 . Uncontrolled glaucoma either eye ( Intraocular Pressure &gt; 24 mmHg ) . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Laser Treatment</keyword>
	<keyword>Visual impairment</keyword>
</DOC>